Tg Therapeutics (TGTX) EPS (Weighted Average and Diluted): 2020-2025
Historic EPS (Weighted Average and Diluted) for Tg Therapeutics (TGTX) over the last 5 years, with Sep 2025 value amounting to $2.43.
- Tg Therapeutics' EPS (Weighted Average and Diluted) rose 12050.00% to $2.43 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.78, marking a year-over-year increase of 2627.27%. This contributed to the annual value of $0.15 for FY2024, which is 66.67% up from last year.
- Per Tg Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at $2.43 for Q3 2025, which was up 1,329.41% from $0.17 recorded in Q2 2025.
- Tg Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at $2.43 during Q3 2025, with a 5-year trough of -$0.71 in Q4 2021.
- Its 3-year average for EPS (Weighted Average and Diluted) is $0.26, with a median of $0.03 in 2025.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first crashed by 97.26% in 2024, then soared by 12,050.00% in 2025.
- Tg Therapeutics' EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.71 in 2021, then rose by 19.84% to -$0.57 in 2022, then skyrocketed by 82.46% to -$0.10 in 2023, then spiked by 250.00% to $0.15 in 2024, then skyrocketed by 12,050.00% to $2.43 in 2025.
- Its last three reported values are $2.43 in Q3 2025, $0.17 for Q2 2025, and $0.03 during Q1 2025.